Scilex Holding Co

Scilex Holding Company’s non‑opioid pain solutions face volatile stock moves, low PE, yet show resilience. Discover its financial outlook and market potential.

Scilex Holding Company boosts its biopharma reach with a $20 M Quantum Scan investment, expanding non‑opioid pain solutions amid volatile biotech markets.

Scilex Holding’s stock swings reveal deep financial woes, but its focus on non‑opioid pain meds could spark a rebound – investors watch closely.

Scilex Holding Co. boosts IP defenses with Kasowitz LLP and cuts share dilution via a $27 M options buyback, positioning itself for growth in the non‑opioid pain market.

Scilex Holding Company is undergoing leadership changes, including the resignation of CEO Jaisim Shah, as the company shifts its focus towards the merger of its subsidiary Semnur Pharmaceuticals with Denali Capital Acquisition Corp.